China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at $17.25 ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public ...

Shares of Ascentage Pharma Group (AAPG) (OTCPK:AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), were trading largely flat Friday following the company's $126M U.S. initial public offering.

Takeda-backed Ascentage Pharma Group (AAPG) has filed to raise up to $100M through a U.S. initial public offering. The Chinese drug developer didn't specify terms in its SEC filing, but indicated ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Ascentage Pharma Group International has filed a registration ...

Jan 23 (Reuters) - Ascentage Pharma (6855.HK), opens new tab said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable ...

Ascentage aims to raise $149 mln via US IPO Plans to offer 7.3 mln American depositary shares at $20.34 each Company's shares already listed in Hong Kong Jan 21 (Reuters) - Ascentage Pharma (6855 ...

The company is based in China but has its U.S. headquarters in Montgomery County. Alexandria dementia care startup opening first physical location © 2025 American ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.